Skills this job asks for
LeadershipProcurementCompliance
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles
- 1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Senior Global Medical Director – Cardio-Renal-Metabolic Disease
About the role
We are looking for a Senior Global Medical Director to provide strategic medical leadership across selected early indication expansion and pipeline opportunities in cardio-renal-metabolic disease. In this highly visible role, you will ensure Medical Affairs insights are incorporated early and consistently into lifecycle strategy, population segmentation, clinical development, integrated evidence planning, scientific differentiation and launch readiness, connecting R&D, Global Product Strategy, Market Access, Evidence Generation and country Medical teams to build a compelling and medically meaningful value proposition for patients, healthcare professionals, payers and health systems.
Key responsibilities
• Lead the global Medical Affairs strategy for assigned indication-expansion opportunities, aligned with overall asset strategy and evolving portfolio priorities.
• Provide senior medical input to indication sequencing, target-population definition, patient segmentation, desired medicine profile, differentiation and the scientific value proposition.
• Partner with Clinical Development on study design, endpoints, data interpretation and the medical relevance of development choices, bringing the external clinical environment and patient pathway into decision-making.
• Lead or co-lead integrated evidence planning for assigned indications, identifying and prioritising evidence gaps across clinical outcomes, PROs, RWE, health outcomes, epidemiology, diagnostics, care pathways and implementation science.
• Drive integrated global scientific communications (publications, congresses, advisory boards, scientific education and other channels) to support robust evidence narratives and core claims.
• Provide targeted Medical Affairs leadership to selected early cardio-renal-metabolic assets, from candidate selection through Commit to Phase 3 or transition to asset-specific medical leads.
• Profile patient pathways and treatment landscapes, define unmet needs and identify evidence and education requirements that shape development choices and future clinical practice.
• Build strong global matrix partnerships across R&D, Evidence Generation, Global Product Strategy, Market Access, Regulatory, Safety, Finance, Procurement and country Medical teams, aligning stakeholders on clear strategic choices and resolving competing priorities.
• Manage project-critical resources, vendors and budgets to deliver agreed milestones with quality and pace.
• Be accountable for appropriate medical governance of strategies, studies, materials and activities, ensuring compliance with the GSK Code of Practice, SOPs and relevant external codes and regulations.
Leadership capabilities
• Strategic enterprise thinking: connecting disease-area science, asset strategy, evidence, access and healthcare delivery.
• Strong scientific judgment: challenging constructively, distinguishing critical evidence from noise and making clear recommendations under uncertainty.
• External orientation: bringing patient, practitioner, payer and health-system perspectives into strategy and understanding the evolving treatment landscape.
• Collaborative leadership: building trust across functions, geographies and cultures and creating alignment around shared outcomes.
• Execution focus: prioritising ruthlessly, converting strategy into high-quality deliverables and maintaining momentum across multiple workstreams.
• Learning agility: rapidly developing expertise and adapting support as indications and early assets progress.
Basic criteria for success (must-have)
• MD/MBBS, PharmD or PhD in a clinical or scientific discipline.
• Experience in cardio-renal-metabolic disease, with direct clinical o
Apply on employer site ↗